The rebalance of the general social security system is mainly based on the decrease in the deficit of the sickness division. Efforts in this direction include lowering the price of drugs. If the direct effect of drug delisting is to reduce treatment supply, any switch to therapeutic classes that are still listed should however be considered.
AASAL is an interesting case study on the impact of drug delisting.
By working on data from the General Beneficiary Sample (EGB) and including data from the Information Systems Medicalisation Program (PMSI), RCTs implemented – via secondary data – a study design that aimed at assessing the impact of AASAL delisting.

Three periods were considered and 19,345 patients, 20,066 patients, and 16,200 patients, were respectively studied in each period.